20231211-西牛证券-清晰医疗-01406.HK-More_time_is_required_to_realize_the_targets_5页_166kb

Clarity Medical's financial performance for the first half of 2023/24 shows a 5.6% YoY revenue decline to HKD 101.6mn, leading to a HKD 20.0mn net loss, primarily due to increased profit sharing, expenses from the New Tsim Sha Tsui Center, and reduced surgery volumes. The core issue stems from stronger competition, which lowered ASPs for SMILE and ICL Implantation Surgery, despite ICL surgeries showing growth with numbers increasing to about 100 per month in Q3. New business in children's prevention and control services offers stable income but at discounted ASPs, requiring more time for marketing and pricing adjustments. To address weak financials, the company plans cost-cutting measures, including doctor portfolio adjustments, potential GFA reduction, and headcount cuts, which may yield improvements in 2024. Financial metrics like operating margin dropped to -0.7%, reflecting heightened risks such as weakening demand for refractive treatments, limited market penetration for new services, and fixed expenses drag. Peer comparison data positions Clarity Medical unfavorably against competitors, with a market cap of HKD 0.3bn and NR stock rating, indicating potential for recovery but significant uncertainties and downside risks. Overall, 2023/24 H1 results suggest a need for strategic adjustments, with possible financial amelioration expected in 2024/25.